Aptevo Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APVO research report →
About the company
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes.
- CEO
- Jeffrey G. Lamothe
- IPO
- 2016
- Employees
- 37
- HQ
- Seattle, WA, US
Price Chart
- Market Cap
- $9.78M
- P/E
- -0.18
- P/S
- 0.00
- P/B
- 0.41
- EV/EBITDA
- -0.27
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -198.50%
- ROIC
- -166.33%
- Revenue
- $0 · 0.00%
- Net Income
- $-25,967,000 · -7.61%
- EPS
- $-87.27 · 99.72%
- Op Income
- $-26,312,000
- FCF YoY
- -7.60%
- 52W High
- $59.40
- 52W Low
- $3.80
- 50D MA
- $4.82
- 200D MA
- $12.83
- Beta
- 1.69
- Avg Volume
- 33.22K
Get TickerSpark's AI analysis on APVO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 25, 26 | NIOWAVE, INC. | other | 0 |
| May 25, 26 | NIOWAVE, INC. | other | 53,201 |
| May 20, 26 | Janatpour Mary Jo | other | 0 |
| Nov 10, 25 | Grant Grady III | buy | 13,513 |
| Oct 1, 25 | BANK OF AMERICA CORP /DE/ | other | 0 |
| Sep 30, 25 | BANK OF AMERICA CORP /DE/ | other | 0 |
| Aug 6, 25 | Abdun-Nabi Daniel | other | 7,200 |
| Aug 6, 25 | Taylor Daphne | other | 11,500 |
| Aug 6, 25 | Grant Grady III | other | 7,200 |
| Aug 6, 25 | Huebner Dirk | other | 11,500 |
Our APVO coverage
Recent articles, reports, and earnings notes.
No research on APVO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate APVO report →Similar companies
Peers in the same neighborhood.